Cyclosporine A is a cyclic peptide widely used in immunology, cell biology, and pharmacology research. It binds cyclophilin and inhibits calcineurin signaling which specifically suppresses NFAT activation and reduces transcription of interleukin-2 and other immune-response genes.
Key Features and Benefits
- Cyclic Peptide: Cyclosporine A is a cyclic undecapeptide with potent biological activity.
- Calcineurin Inhibitor: The cyclosporine-cyclophilin complex inhibits the phosphatase activity of calcineurin.
- NFAT Signaling: Calcineurin inhibition specifically reduces NFAT dephosphorylation and nuclear translocation.
- T-Cell Research: Commonly used to investigate T-cell activation and immune signaling pathways.
- IL-2 Regulation: Suppresses IL-2 transcription through inhibition of calcineurin-NFAT signaling.
- Research Standard: Widely studied in immunology, transplantation biology, pharmacology, and drug metabolism research.
Applications
- Immunology Research: Used to investigate immune activation and immunosuppressive mechanisms.
- T-Cell Signaling: Supports studies of T-cell receptor signaling and downstream cellular responses.
- Calcineurin-NFAT Research: Used to investigate calcineurin-dependent NFAT signaling pathways.
- Cytokine Research: Supports studies specifically involving IL-2 and other immune-related gene responses.
- Drug Metabolism Research: Used in pharmacokinetic, transporter, CYP3A, and drug-interaction studies.
Storage and Handling
- Storage: Store according to the product specification in a tightly sealed container. Protect from moisture, light, and excessive heat.
- Handling: Follow appropriate laboratory procedures and product-specific safety documentation.
Cyclosporine A is a well-characterized research compound for studying calcineurin-NFAT signaling and T-cell activation that also supports immunology, cytokine regulation, pharmacology, and drug metabolism research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.






